DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/htlxh6/flovent_asthma) has announced the addition of the "Flovent (Asthma) - Forecast and Market Analysis to 2023" report to their offering.
Originally approved by the Food and Drug Administration (FDA) in 1996, GSK's Flovent (fluticasone propionate) is a synthetic ICS therapy with potent anti-inflammatory activity. It is used for the maintenance treatment of asthma prophylactically in children and adults. Flovent is now available in two formulations, Diskus and HFA, which received the FDA approval in 2000 and 2004, respectively. Flovent's active ingredient, fluticasone propionate, can bind to glucocorticoid receptors with high affinity and inhibit the secretion of mediators involved in asthma, such as histamine, eicosanoids, leukotrienes, and cytokines. It is three times more potent than budenoside, and two times more potent than the active metabolite of beclomethasone dipropionate.
- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Flovent including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Flovent for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Flovent (fluticasone propionate)
For more information visit http://www.researchandmarkets.com/research/htlxh6/flovent_asthma